Prices are updated after-hours

Professional, Scientific, and Technical Services 2022 - 06 - 03

Kallo Inc.

KALO | $0.0003 24900.0% 100

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-97.98% volume)
Earnings Calendar:
Market Cap: $ 1,906,929

Sec Filling | Patents | 4 employees

kallo offers a comprehensive healthcare delivery program dedicated to providing the most technologically advanced, innovative healthcare solution that is customized to the requirements of each country, including effective infectious disease management and customized education and training programs. the company's technology suite transforms healthcare delivery via rural healthcare, disease management, clinical globalization and ehealth solutions. for more information on kallo and ongoing business developments, please visit us at www.kalloinc.ca

education

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.691 -4.57% -4.79% 20K

Professional, Scientific, and T...

(0.0% 1d) (-28.1% 1m) (16.4% 1y) (0.0% 2d) (0.0% 3d) (-10.3% 7d) (-53.24% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,744,991
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $11.18 -2.78% -2.86% 1.7M

Professional, Scientific, and T...

(0.0% 1d) (-22.0% 1m) (-56.5% 1y) (0.0% 2d) (0.0% 3d) (-7.9% 7d) (-13.61% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 401,243,045
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.4 -4.76% -5.0% 26K

Professional, Scientific, and T...

(0.0% 1d) (-9.7% 1m) (-78.1% 1y) (0.0% 2d) (-18.7% 3d) (24.1% 7d) (-81.77% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,853,831
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $5.87 0.51% 0.51% 120K

Professional, Scientific, and T...

(0.0% 1d) (-1.7% 1m) (136.4% 1y) (0.0% 2d) (4.1% 3d) (24.5% 7d) (-3.7% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 254,449,021
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

iCoreConnect Inc.

ICCT | $1.2 0.0% 62K

Professional, Scientific, and T...

(0.0% 1d) (-4.8% 1m) (823.1% 1y) (0.0% 2d) (-4.8% 3d) (-9.1% 7d) (-63.12% volume)
Earnings Calendar:
Market Cap: $ 10,741,766

Sec Filling | Patents | 25 employees

icoreconnect creates software that allows anyone to share information at the highest security levels in the country, backed by highly-engaged customer support. the company provides secure communications for high-compliance industries including healthcare, finance and legal. icoreconnect’s software allows organizations and individuals to freely and easily exchange information with 2048-bit encryption, and in full compliance of current federal laws.

communication

add to watch list Paper trade email alert is off

Reneo Pharmaceuticals Inc

RPHM | $1.76 -0.57% -0.57% 76K

Professional, Scientific, and T...

(0.0% 1d) (7.3% 1m) (-80.2% 1y) (0.0% 2d) (7.3% 3d) (2.3% 7d) (616.69% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 58,820,622
https://reneopharma.com
Sec Filling | Patents | 32 employees

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

energy renewable genetic metabolic

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | $3.855 -1.41% -1.43% 260K

Professional, Scientific, and T...

(0.0% 1d) (-20.9% 1m) (-46.3% 1y) (0.0% 2d) (0.0% 3d) (-3.6% 7d) (100.14% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 189,437,518
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

Inhibitor Therapeutics, Inc.

INTI | $0.0685 42.57% 400

Professional, Scientific, and T...

(0.0% 1d) (11.1% 1m) (159.3% 1y) (0.0% 2d) (-4.8% 3d) (-4.8% 7d) (-92.16% volume)
Earnings Calendar:
Market Cap: $ 11,779,817
http://www.hedgepathpharma.com/
Sec Filling | Patents | 2 employees

(US) hedgepath pharmaceuticals inc is a company based out of 324 s hyde park ave, tampa, fl, united states.

add to watch list Paper trade email alert is off

Alpha Teknova Inc

TKNO | $2.01 -4.74% -4.98% 13K

Professional, Scientific, and T...

(0.0% 1d) (-24.9% 1m) (-0.5% 1y) (0.0% 2d) (-18.8% 3d) (-12.4% 7d) (952.9% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 82,055,008
https://www.teknova.com
Sec Filling | Patents | 193 employees

Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.

diagnostics gene therapies t-cell

add to watch list Paper trade email alert is off

Entrada Therapeutics Inc

TRDA | $11.91 -2.54% -2.6% 130K

Professional, Scientific, and T...

(0.0% 1d) (-3.8% 1m) (-19.8% 1y) (0.0% 2d) (-3.9% 3d) (-5.6% 7d) (13.78% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 400,189,137

Sec Filling | Patents | 2021 employees

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

add to watch list Paper trade email alert is off

Emmaus Life Sciences, Inc.

EMMA | $0.1138 385.44% 300

Professional, Scientific, and T...

(0.0% 1d) (32.7% 1m) (-65.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-91.48% volume)
Earnings Calendar:
Market Cap: $ 7,038,071
https://www.emmausmedical.com/
Sec Filling | Patents | 57 employees

(United States) emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.

t-cell

add to watch list Paper trade email alert is off

ECO INNOVATION GROUP, INC.

ECOX | $0.0001 0.0% 72M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (100.0% 1y) (0.0% 2d) (0.0% 3d) (33.3% 7d) (-36.3% volume)
Earnings Calendar:
Market Cap: $ 243,235

Sec Filling | Patents | n/a employees

eco innovation group, inc. provides water treatment unit to convert contaminated water into safe drinking water. the company is based in palm beach, florida.

add to watch list Paper trade email alert is off